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Abstract: Chemotherapeutics represent the standard treatment for a wide range of cancers. However,
these agents also affect healthy cells, thus leading to severe off-target effects. Given the non-selectivity
of the commonly used drugs, any increase in the selective tumor tissue uptake would represent a
significant improvement in cancer therapy. Recently, the use of gene therapy to completely remove
the lesion and avoid the toxicity of chemotherapeutics has become a tendency in oncotherapy. Ideally,
the genetic material must be safely transferred from the site of administration to the target cells,
without involving healthy tissues. This can be achieved by encapsulating genes into non-viral carriers
and modifying their surface with ligands with high selectivity and affinity for a relevant receptor on
the target cells. Hence, in this work we evaluate the use of terpolymer-based nanocapsules for the
targeted delivery of DNA toward cancer cells. The surface of the nanocapsules is decorated with folic
acid to actively target the folate receptors overexpressed on a variety of cancer cells. The nanocapsules
demonstrate a good ability of encapsulating and releasing DNA. Moreover, the presence of the
targeting moieties on the surface of the nanocapsules favors cell uptake, opening up the possibility of
more effective therapies.
Keywords: polymeric nanoparticles; nanocapsules; gene therapy; active targeting; DNA delivery;
folic acid; terpolymer; cancer
1. Introduction
Chemotherapy is the major therapeutic approach for the treatment of a wide range
of cancers. A major problem with such treatment is represented by side effects as the
agents affect healthy tissues as well as cancerous cells [1–3]. Hence, any selective increase
in tumor tissue uptake would be a significant improvement in cancer therapy given
the non-selectivity of the commonly used drugs [4]. With the progress in molecular
biology and biotechnology, most cancers have been discovered to be caused by genetic
mutations [5–10]. Consequently, gene therapy has been acknowledged as major progress
of modern medicine and a focus for oncotherapy research. In particular, the application of
gene therapy to completely remove the lesion and avoid the serious overall toxicity and
side effects becomes a tendency in the development of oncotherapy [11–15]. Specifically,
in oncotherapy cancer cells can be modified with genes of cytotoxic or tumor suppressive
proteins, or with a class of suicidal genes in combination with pro-drugs, all of which
Biomedicines 2021, 9, 1275. https://doi.org/10.3390/biomedicines9091275 https://www.mdpi.com/journal/biomedicines
Biomedicines 2021, 9, 1275 2 of 17
result in autonomous cell death [16]. Alternatively, the anti-tumor immune response can
be elicited by genetic modification of malignant cells or immune cells to produce cytokines
or tumor antigens. Generally, the genetic material must be safely transferred from the site
of administration to the target cells. Depending on the nature of the carrier, there are two
different approaches for gene delivery, consisting in viral and non-viral delivery [5,17–20].
In particular, viral vectors mediate gene transfer with high efficiency and can ensure long-
term gene expression, however there are many safety concerns related to their use including
vector antigenicity, inflammation, and possible insertional mutagenesis [5,21]. On the other
hand, non-viral vectors have presented some crucial advantages over viral vectors to
improve the toxicity and targeting problems by using nanotechnology in tumor tissues.
These carriers include lipids, biomaterials, synthesized polymers, and dendrimers [22–28].
In all cases, the main goal is to select the target cells with a reduction in the number
of non-cancer cells affected, thus reducing systemic side effects [29,30]. An example is
represented by the active targeting, also called ligand-mediated targeting, by exploiting
specific ligands on the surface of the non-viral carrier, with high selectivity and affinity for
a relevant receptor on the target cells [31]. This approach is beneficial in terms of enhancing
accumulation at the target site and decreasing the exposure of healthy cells to the drug.
Active targeting has been efficiently exploited to increase nanoparticle internalization by
target cells and improve the efficacy of their payloads [32–36].
Ligands are selected to bind surface molecules or receptors overexpressed in dis-
eased organs, tissues, cells or subcellular domains. In the development of anti-tumor
agents, including DNA, much attention has been given to systems targeting the folate
receptors [37–45]. The folate receptor is an affinity membrane folate-binding protein which
after folic acid binding trigger endocytosis with consequent cell uptake. Its expression
is negligible in healthy cells while it is largely present in myeloid leukemia [46] and
various solid tumors such as lung, brain, ovarian, prostate, breast, gastric and colorec-
tal [47]. Over expression of folate receptors on cancer cells makes it a potential target [48].
For this reason, it has been exploited by diagnostic tools for bioimaging of tumor cells [49].
Moreover, advantages of a small targeting ligand like folic acid over larger entities are repre-
sented by limited changes in dimensions of the carrier and lower or absent antigenicity [50].
In this study we evaluated our previously developed and fully characterized terpolymer-
based nanoparticles [51] to be used for targeted DNA delivery, using folic acid as ligand
to obtain active targeting toward cancer cells. Nanoparticles were fabricated in the form of
nanocapsules due to their increased ability to encapsulate and release the active principle
of interest.
2. Materials and Methods
All the materials and reagents were obtained from Sigma-Aldrich (Sigma-Aldrich,
Milan, Italy) unless otherwise specified.
2.1. Preparation of Nanocapsules
Terpolymer-based nanocapsules (NCs) were fabricated following the same protocol
described in our previous paper [51]. Briefly, NCs were obtained by radical polymer-
ization starting from a diluted solution of butyl methacrylate (BMA, Mw: 142.2 g/mol,
density: 0.894 g/cm3), poly(ethylene glycol) methyl ether methacrylate ((PEG)MEMA,
Mw: 300 Da, density: 1.05 g/mL) and 2-(dimethylamino)ethyl methacrylate (DMAEMA,
Mw: 157.21 g/mol, density: 0.933 g/mL), with 80/10/10 percentage molar ratio and in
the presence of trimethylpropane trimethacrylate (TRIM) as cross-linker (20% mol/mol).
The chemical structures of the monomers and cross-linker used for the synthesis are shown
in Table 1.
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Table 1. Chemical structures of the monomers used for the synthesis of the sacrificial core (MMA),






Poly(ethylene glycol) methyl ether
methacrylate (PEG)MEMA
Trimethylpropane trimethacrylate (TRIM)
The polymerization was carried out around a preformed polymeric core. First, poly-
methyl methacrylate (PMMA)-based nanoparticles to be used as the sacrificial core were
synthesized by emulsion polymerization of methyl methacrylate (MMA, Mw: 100.12 g/mol,
density: 0.940 g/cm3) in the presence of sodium dodecyl sulfate (SDS, Mw: 288 g/mol)
as surfactant. The polymerization was carried out in a mixture of water/ethanol (60/40
v/v) in the presence of sodium metabisulfite (Na2S2O5, Carlo Erba Reagenti, Milan, Italy)
and ammonium persulfate ((NH4)2S2O8, Carlo Erba Reagenti, Milan, Italy) as the radical
initiator (10% mol/mol). Subsequently, radical polymerization of monomers around the
preformed core (PMMA core/monomers weight ratio 1:5) was performed. The reaction
was carried out for 3 h at 37 ◦C, ensuring a constant stirring at 600 rpm. At the end of
the polymerization, PMMA core was extracted by three cycles of washing in chloroform
(Carlo Erba Reagenti, Milan, Italy) followed by rinsing with water. NCs were freeze-dried
overnight and stored at 4 ◦C until further use.
2.2. Covalent Functionalization
NCs were covalently functionalized to obtain active targeting towards cancer cells,
using folic acid (FA, Mw: 441.4 Da) as the ligand to be bound on the surface of the nanopar-
ticles. First, carboxyl groups of FA were activated to favor the interaction with the amino
groups of the material. A 0.045 M FA solution in dimethyl sulfoxide (DMSO) was prepared.
Subsequently, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-Hydroxysuccinimide
(EDC/NHS) were added (FA/EDC molar ratio 1:1, EDC/NHS molar ratio 3:1) and the
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solution was kept under mild magnetic stirring at room temperature for 18 h to favor the
activation of the FA carboxyl groups. At the end of the incubation period, the unreacted
EDC/NHS was removed via dialysis against water. Once FA was activated, NCs were
dispersed in the solution (NCs/FA weight ratio 1:1) by sonicating them for 1 min at the max-
imum power using a bath sonicator (Branson 1800) and then kept under magnetic stirring
at room temperature for 3 h. Finally, NCs were centrifuged (Mikro 200 Hettich Zentrifugen,
Tuttlingen, Germany) at 14,000 rpm for 15 min and washed three times with bidistilled
water to remove the excess of FA. A schematic of the reaction is shown in Figure 1.
Figure 1. Schematic of the coupling reaction between folic acid (FA) and terpolymer-based nanopar-
ticles (NPs). Activation of carboxylic groups of FA (chemical structure shown at the top right)
by EDC/NHS; formation of covalent bonds among activated esters of FA and tertiary amine of
DMAEMA monomer units of terpolymer-based nanoparticles.
Moreover, adsorption of FA was carried out on NCs to have a control for comparison to
the covalently functionalized ones. Adsorption was carried out following the same protocol
used for the functionalization, using non-activated FA. Subsequently, functionalized NCs
and NCs after FA adsorption were dispersed in phosphate buffer solution (PBS) by bath
sonication for 1 min at the maximum power, and then kept under vigorous magnetic stirring
for 1 h at 70 ◦C. Samples were centrifuged at 14,000 rpm for 15 min, the supernatant was
completely removed and fresh PBS was added. This procedure was repeated three times.
The purpose of this treatment was to demonstrate the validity of the process of covalent
functionalization. The hypothesis is that after the treatment, FA is no longer present on
NCs after adsorption while it continues to be present on covalently functionalized NCs.
The amount of conjugated FA on the NCs (conjugation efficiency) was quantified
via absorbance measurements at a wavelength of 280 nm using a spectrophotometer
(Shimadzu UV-2100). Specifically, the amount of FA remained in the solution used for the
conjugation procedure was analyzed at the end of the incubation period, and the amount
of conjugated FA was calculated as the difference between the initial amount of FA in the
solution and the amount of FA that remained in the solution at the end of the incubation
period. The same method was used to analyze the solutions at the end of the extraction
procedure to investigate the presence of FA, if any.
2.3. Characterization of the Nanocapsules
2.3.1. Monomer Conversion
To evaluate the final monomer conversion, an aliquot of the polymerization media was
collected at the end of the synthesis and analyzed via High Performance Liquid Chromatog-
raphy (HPLC, Perkin Elmer Series 200, Waltham, MA, USA). The mobile phase consisted
of acetonitrile (ACN)/water (80/20 v/v) pumped at an isocratic flow rate of 1 mL/min.
The analysis was carried out using an Alltima C18 5u (Alltech, 250 mm × 4.6 mm) as a
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where C0 and Ct are the initial and final monomer concentrations in the reactive mass,
respectively.
2.3.2. Morphological Analysis
The morphology of the PMMA sacrificial core, as well as the morphology of the NCs
before and after the extraction of the core was examined by scanning electron microscopy
(SEM JEOL JSM 5600, Jeol, Tokio, Japan). Samples were placed on the SEM sample
stage and sputter-coated with gold. Quantitative information regarding the mean size and
polydispersity index (PDI) of the NCs was obtained by dynamic light scattering (DLS) using
a Zetasizer Malvern nano ZS90 (Malvern, U.K.). The analyses were carried out in triplicate
by dispersing the NCs in ethanol, since it represents the most suitable dispersant medium
to reduce nanoparticle aggregation, as previously demonstrated by the authors [51].
2.3.3. Physicochemical Analysis
Fourier-transform infrared spectroscopy (FT-IR) was carried out to obtain information
regarding the composition of the NCs using a Spectrum Spotlight Imaging System (Perkin
Elmer, Waltham, MA, USA). The same technique was suitable also for the evaluation of
the successful removal of the PMMA sacrificial core to form the final hollow nanoparticles,
as previously demonstrated by the authors and others [51,52]. Finally, FT-IR analysis was
performed to investigate the formation of a stable bond between the polymeric matrix and
FA in covalently functionalized NCs.
2.4. Cytotoxicity Test
2.4.1. MTT Assay
To evaluate the cytocompatibility of the NCs, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenil tetrazolium bromide (MTT) assay was performed using NIH3T3 mouse fibrob-
last cell line (Cell bank Interlab Cell Line Collection, ST Genova, Italy). NCs were ex-
tracted in Dulbecco’s Eagle’s Modified Medium (DMEM) (20 mg/mL) for 24 h at 37 ◦C.
Cells were seeded in 48-well plates at two different densities: 1.2 × 104 cells/cm2 and
0.6 × 104 cells/cm2 for the 24- and 72-h exposure period, respectively. At 24 h after seed-
ing, culture medium was removed from each well and replaced with 800 µL of fresh
culture medium and 200 µL of sterile filtered NC extract to reach the final concentration of
100 µg/mL. No extracts were added to 12 wells used as negative control. Samples were
incubated at 37 ◦C with 5% CO2. After 24 and 72 h, 100 µL of MTT solution was added
to each well. After an additional 4-h incubation period, medium was replaced with 1 mL
DMSO and absorbance was read at 570 nm using an UV spectrophotometer (JASCO; V530,
Lecco, Italy).
2.4.2. Propidium Iodide Flow Cytometry Assay
To further evaluate the cytocompatibility of the NCs, Propidium Iodide was used for
cell viability assays through FACS analysis. HELA cells and NIH3T3 cells were separately
seeded in a 24-well plate. An amount of 5 × 104 and 2.5 × 104 cells per well were seeded
for the 24- and 72-h exposure period, respectively. Cells seeded alone were used as negative
control. At 24 h after seeding, culture medium was removed from each well and replaced
with 800 µL of fresh culture medium and 200 µL of sterile filtered NC extract to reach the
final concentration of 100 µg/mL. After 24 and 72 h of culture cells were detached with
Trypsin-0.2% EDTA, resuspended in 500 µL of cold 1X PBS (Sigma-Aldrich) and transferred
into Falcon tubes for flow cytometry analysis. Then, 10 µL of Propidium Iodide (1:20 in
bidistilled water, Sigma-Aldrich) were added and after 5 min cell viability was analyzed
through flow cytometry. The experiments were carried out in triplicates for each condition.
2.5. Nucleic Acid Adsorption and Release Tests
To verify the possibility to use functionalized NCs for the targeted release of nucleic
acids, their ability to load and then release DNA was investigated. Adsorption tests were
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carried out using a model molecule of DNA (Deoxyribonucleic acid, low molecular weight
from salmon sperm). DNA was dissolved in PBS (10 mg/mL), NCs were added to DNA
solution (1 mg/mL), vortexed to favor the dispersion, and gently stirred for 2 h. At the end
of the incubation period, NCs were collected via centrifugation at 14,000 rpm for 15 min.
Release tests were performed by adding PBS to the NCs, and vortexing them to favor
the dispersion in the release medium. Samples were kept under rotation at 37◦C for the
entire duration of the release study. Aliquots of the release medium were collected at
predetermined time points and fresh PBS was added. Both adsorption and release tests
were carried out in triplicate.
The amount of absorbed and released DNA was investigated by High Performance Liq-
uid Chromatography (HPLC, Perkin Elmer Series 200, Waltham, MA, USA). Samples were
analyzed using a Synergy 4u Hydro-RP C18 (80 Å, 250 mm × 3.00 mm; Phenomenex, Tor-
rance, CA, USA) as a column and acetonitrile (ACN)/water (7/93 v/v), fluxed at 1 mL/min
as the internal mobile phase. The injected volume was 50 mL, and the chromatograms
acquired at the UV wavelength of 260 nm were used for quantitative analysis. The release
kinetics was analyzed using the semi-empirical equation of the power low to describe drug




where Mt and M∞ are the absolute cumulative amounts of drug released at time t and
infinite time, respectively, k is a constant incorporating structural and geometric char-
acteristics of the device, and n is the release exponent, indicative of the drug release
mechanism [53,54].
2.6. Cell Uptake Test
To investigate the ability of functionalized NCs to actively target cancer cells, cell up-
take tests were carried out using human cervix epithelioid carcinoma HeLa cells, obtained
from the American Type Culture Collection (LGC Promochem, Molsheim, France) having
overexpressed FA receptors [55]. Non-functionalized NCs were used as control. NC sur-
face was decorated with a fluorescent dye (Fluorescein, Fluo, molecular weight 332.31 Da)
to make samples traceable. Specifically, the carboxyl group of Fluo was activated using
EDC/NHS (Fluo/EDC molar ratio 1:1, EDC/NHS molar ratio 3:1) to favor the formation
of a stable bond with NPs. Subsequently, NCs were dispersed in Fluo solution (NCs/Fluo
molar ratio 1:1) and stirred for four hours. Finally, NCs were centrifuged at 14,000 rpm for
15 min and washed three times with bidistilled water to remove the excess of Fluo.
2.6.1. Flow Cytometric Detection of Functionalized and Non-Functionalized NC Uptake
HeLa cells were seeded at a density of 5 × 103 cells/well in complete DMEM,
and plates were incubated at 37 ◦C with 5% CO2 for 24 h to achieve a monolayer. To deter-
mine the IRIS Dots uptake and loading contents, cells were incubated with a suspension
of NCs (100 µg/mL) in complete DMEM for various incubation times. Cells were then
washed twice with phosphate-buffered saline (PBS; Gibco Invitrogen, Milan, Italy) and
harvested by trypsinization. Cells were resuspended in PBS and the fluorescence emission
of NCs (FL-1) was analyzed on a CyAN ADP flow cytometer using the Summit 4.3 software
(Beckman Coulter, Fullerton, CA, USA). About 10,000 cells were measured for each sample.
Cell debris signals were removed using morphological criteria.
2.6.2. Confocal Microscopic Detection of Functionalized and Non-Functionalized
NC Uptake
To detect the uptake of NCs, HeLa cells were seeded at 10,000 cells cm−2 in sterile
eight-well µ-slides (Ibidi GmbH, Martinsried, Germany) and allowed to attach for 24 h.
Cells were incubated with functionalized and non-functionalized NCs (100 µg/mL) in
complete medium for 24 h. Then, the cells were washed three times with PBS and fixed with
4% paraformaldehyde. The cells were mounted with Mowiol (Calbiochem, San Diego, CA,
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USA). Fluorescence images were obtained with a 510 Carl Zeiss confocal laser microscope
using a 63× objective.
2.7. Statistics
All the experimental data were expressed as mean ± SD (n = 3 unless otherwise
specified).
F-test was performed on viability measurements to determine statistically significant
differences, if any, in cell viability. Statistically significant differences were designated by a
significance criterion (p value) below 0.05.
3. Results
In this study, previously developed terpolymer-based NCs were functionalized using
FA to actively target DNA towards cancer cells.
Terpolymer-based NCs were characterized for physical and chemical properties before
functionalization with FA. The physico-chemical characterization of NCs before functional-
ization confirmed the results highlighted in a previous published study, supporting the
reproducibility of the production process [51]. Briefly, the radical polymerization of the
three monomers led to the formation of NCs directly in the reaction phase, with a monomer
conversion around 100% for BMA and (PEG)MEMA, and higher than 95% for DMAEMA
(Figure 2a).
Figure 2. (a) Percentage conversion for each monomeric unit; SEM representative micrographs of (b) PMMA sacrificial core,
(c) NCs before and (d) after extraction of the core.
SEM analysis highlighted nanometric dimensions and spherical shape of the PMMA
core and NCs with a rather homogeneous distribution, and a modest state of aggregation
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(Figure 2b,c). This was confirmed by DLS measurements that returned an average diameter
of the NCs of 224.95 ± 48.43 nm and a PDI of 0.77. Additionally, no significant differences
were observed in the morphology of the NCs before and after extraction of the sacrificial
core (Figure 2c,d). FT-IR analysis confirmed the previously published results [51], high-
lighting the presence of the three components in the NCs and confirmed the formation of
their hollow structure (data not shown).
3.1. Covalent Functionalization
NCs were functionalized by covalently binding FA to their surface to obtain active
targeting toward cancer cells. The spectra related to pure FA, terpolymer-based NCs,
functionalized NCs before and after removal of FA, and NCs after adsorption of FA before
and after removal were acquired. FA spectrum showed the diagnostic band around
1600 cm−1, which is related to the absorption of the carbonyl group (Figure 3a).
Figure 3. FT-IR analysis. (a) Spectrum of folic acid; (b) comparison among the spectra of pure terpolymer-based NCs,
functionalized NCs, and NCs after adsorption of FA before extraction and (c) a magnification; (d) comparison between of pure
terpolymer-based NCs, functionalized NCs, and NCs after adsorption of FA after removal procedure, and (e) a magnification.
The same absorption band was evident in functionalized NCs (Figure 3b,c), and it was
still present after the removal process (Figure 3d,e), confirming the formation of a stable
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bond. This result was confirmed by the spectra of NCs after adsorption (Figure 3b,c) and
removal (Figure 3d,e) of FA. In fact, the diagnostic band was evident in the spectra of NCs
after FA adsorption but it was not present in the spectra of NCs after forced removal of the
ligand, confirming the formation of a more stable bond in the case of functionalized NPs.
The conjugation efficiency was evaluated by analyzing the solutions at the end of the
conjugation and at the end of the three washings by absorbance measurements at a wave-
length of 280 nm. The analysis returned a conjugation efficiency of 33.6%, corresponding
to a mg FA/g NCs of 336, confirming the suitability of the procedure used for a successful
formation of a stable bond between the polymer matrix and the activated FA.
3.2. In Vitro Cytotoxicity
The cytocompatibility of NCs after covalent functionalization with FA was inves-
tigated using both the in vitro MTT assay and the Propidium Iodide Cytometry assay.
Specifically, extracts of NCs (corresponding to a concentration of FA of 33.6 µg/mL) were
added to NIH3T3 and HeLa cells and the viability after 24 and 72 h of exposure was
evaluated. Figure 4 shows that the mitochondrial activity of NIH3T3 cells was not affected
by the NC extracts neither after 24- nor 72 h-incubation period.
Figure 4. In vitro cytotoxicity tests. (a) Cytotoxicity MTT assay of functionalized NCs after 24- and
72-h incubation with NIH3T3 cells. A comparison with negative control is shown; (b) Propidium
Iodide Flow Cytometry assay of functionalized NCs after 24- and 72-h incubation with HeLa cells.
A comparison with negative control is shown; (c) Propidium Iodide Flow Cytometry assay of
functionalized NCs after 24- and 72-h incubation with NIH3T3 cells. A comparison with negative
control is shown (* p < 0,05; t-test; mean ± SD; n = 3).
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The absorbance values acquired by spectrophotometric analysis were subjected to
statistical analysis using the F-test, which provided F values smaller than the critical one
for all the systems tested, with p > 0.05. This result indicates that there are no significant
differences between treated cells and negative control. Propidium Iodide Flow Cytom-
etry assay confirmed optimal cell viability at 24 and 72 h for both cell lines. After 24 h,
a minimal cytotoxicity was evidenced for NIH3T3 cells only, but no difference was noticed
at 72 h versus the negative control, confirming the non-cytotoxicity of the particles after
functionalization.
Overall, the obtained results suggest that the modification of the nanoparticles with
FA did not affect their cytocompatibility.
3.3. Nucleic Acid Adsorption and Release Tests
DNA adsorption and release tests were performed on functionalized NCs to deter-
mine if the functionalization affected the interactions between polymer and nucleic acid.
DNA adsorption test carried out on functionalized NCs showed an adsorption efficiency
around 54%, which was lower than the adsorption efficiency of the non-functionalized
NCs (87.1%), as shown in Figure 5a.
Figure 5. DNA adsorption and release assay. (a) DNA adsorption into non-functionalized and functionalized NCs;
(b) percentage cumulative release of DNA from functionalized NCs. The inset represents a comparison of DNA released
from functionalized NCs and non-functionalized NCs expressed as total mass released.
Biomedicines 2021, 9, 1275 11 of 17
DNA release from functionalized NCs was also investigated. Figure 5b shows a DNA
release profile characterized by an initial burst effect typical of such kind of nanoparticles
followed by a constant release with controlled kinetics over time, with almost 60% DNA
released over a period of 30 days. The comparison between the DNA released from non-
functionalized NCs and functionalized NCs showed for the latter a reduction in the initial
burst effect and a more linear release profile over time.
3.4. Cell Uptake
Cell uptake tests were carried out on covalently functionalized, fluorescinated NCs
using HeLa cells to investigate their ability to actively target cancer cells overexpressing
FA receptors. Non-functionalized, fluorescinated NCs were used as control. In a first
set of cellular uptake experiments, HeLa cells were incubated with 100 µg/mL of either
functionalized or non-functionalized NCs in complete medium for various incubation
times (6 and 24 h) at 37 ◦C. After the indicated time, the cells were trypsinized and cellular
uptake of the two types of NCs was determined by flow cytometry. Uptake of NCs began
as early as 6 h after incubation and increased at 24 h, thus revealing that NCs uptake was
time-dependent (Figure 6a,b).
Figure 6. Cell uptake test. Fluorescence-activate cell sorting (FACS) analysis representing the dot
plots of physical cell parameters and histogram plots of fluorescence emitting HeLa cells after (a) 6-h
and (b) 24-h incubation with functionalized and non-functionalized NCs. Black histograms represent
cells stained with 100 µg/mL−1 NCs. Gray histograms represent unstained control cells; (c) confocal
microscopy images of HeLa cells after 24 h of incubation with 100 µg mL−1 functionalized and
non-functionalized NCs. Scale bar 20 µm.
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Interestingly, this analysis highlighted a higher percentage of emitted fluorescence
in the case of covalently functionalized NCs than control NCs, thus suggesting that FA-
functionalization was effective in augmenting internalization rate (Figure 6 and Table 2).
Table 2. FACS analysis. Percentage of HeLa cells emitting fluorescence at the different time points.
Functionalized NCs Non-Functionalized NCs
% Count % Count
6 h 12.45 6.69
24 h 40.23 21.77
In a further set of experiments, HeLa cells were plated in sterile eight-well µ-slides and
incubated for 24 h with NCs, then the cells were washed twice to remove the excess NCs pas-
sively adsorbed on the cell surface and imaged by confocal microscopy. Both functionalized
and non-functionalized NCs entered the cells and in 24 h they could be localized either near
the cell membrane or distributed inside the cell cytoplasm (Figure 6c). In agreement with
the quantitative FACS analysis of cellular uptake (Figure 6a,b), increased internalization
was observed in the case of functionalized NCs compared to the non-functionalized ones,
confirming a higher ability of the functionalized NCs to be uptaken by cells overexpressing
FA receptors (Figure 6c).
4. Discussion
The radical polymerization of BMA, DMAEMA, and PEG was carried out to synthesize
innovative terpolymer-based NPs with properties suitable for the encapsulation of nucleic
acids. The development of a three component-based copolymer was triggered by the need
to develop a drug delivery system capable of enhancing the loading and the release of DNA,
thanks to the combination of the properties of each element. Specifically, the acrylic polymer
PBMA is well known for its biocompatibility, and it has been used to fabricate platforms
for gene delivery [56–58]., Given its chemical properties and low toxicity, pDMAEMA has
been largely utilized as non-viral gene delivery system [59,60]. Finally, PEG chains were
introduced to make the surface of the NPs more hydrophilic and minimize the protein
absorption, thus reducing the reticuloendothelial clearance [61,62].
The template polymerization of the three distinct monomers around a preformed
polymeric core led to the formation of hollow NCs with a spherical shape and nanometric
dimensions. FT-IR analysis highlighted the success of the copolymerization, confirming the
HPLC results that showed a monomer conversion greater than 95% for all the monomers.
Furthermore, the analysis pointed out the removal of the PMMA core that led to the
formation of the hollow structure of the NCs.
To obtain active targeting towards cancer cells, NCs were covalently functionalized
with FA, and FT-IR analysis was performed to verify the formation of a stable bond.
Indeed, FA is an essential molecule in DNA synthesis pathway which is highly needed for
cancer cell duplication. As a consequence, many cancer cells overexpress folate receptors
higher than normal cells, and this fact is the basis of the folate targeting strategy [47].
The comparison between the spectra acquired on functionalized NCs and control NCs after
adsorption of FA showed the presence of the diagnostic band around 1600 cm−1 due to
the absorption of the carbonyl group of the FA in both samples before the removal of the
ligand under drastic conditions. The FA diagnostic band was still evident in the spectra
of functionalized NCs after the removal procedure, while it was not present anymore in
the spectra of NCs after FA adsorption and subjected to the same FA removal procedure,
suggesting that the covalent functionalization was successful. This might be due to the
formation of a stable bond between the activated carbonyl group of FA and the amino
group of the pDMAEMA, while the interactions occurring between FA and NCs during the
adsorption procedure were not stable enough, thus leading to the removal of the ligand
after repeated washings.
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In view of a possible use of these nano-systems for the delivery of a nucleic acid to
treat pathologies such as cancer, DNA with a low molecular weight was selected as the
model molecule to be encapsulated into NPs. NCs showed a good adsorption efficiency,
mainly due to the formation of hydrogen bonds between NCs and DNA, in addition to the
presence of pDMAEMA, which provides amino groups to the terpolymer that favor the
molecular interaction [63–65]. Interestingly, the adsorption efficiency of the functionalized
NCs was lower than the adsorption efficiency of the non-functionalized ones. This might
be due to part of the functional groups of the pDMAEMA interacting with the carboxyl
group of the FA, leading to less amino groups available for the interaction with the DNA.
Despite this, the capability of the NCs to release DNA with a controlled trend was not
affected by the lower adsorption efficiency. In fact, the release assay carried on NCs after
covalent functionalization highlighted a more controlled kinetics if compared to the one
of non-functionalized NCs, with a reduction of the initial amount of DNA released and a
more constant release over time. Analyzing the release profile more in depth, the initial
burst effect was probably due to the DNA weakly bound to the surface of the NCs and/or
to the polymeric matrix immediately below the surface. In the subsequent phase, the DNA
release slowed down and it was prolonged over time. The more controlled release kinetics
might be due to the presence of FA on the surface of the NPs, forming an additional layer
through which DNA has to diffuse before being released. In addition, after 30 days, only
60% of the absorbed DNA was released, suggesting that the nucleic acid in the inner part
of the cavity needs more time to diffuse through the polymer and be delivered. Overall,
terpolymer-based NCs, thanks to their composition and hollow structure, represent a
delivery system capable of enhancing the amount of encapsulated DNA, as well as leading
to a more prolonged release over time. Indeed, many polymeric drug delivery systems
have been investigated for the delivery of nucleic acid; however, the loading of DNA is
often lower than 50% with a fast release in the order of hours [66–69].
In addition, release kinetics was analyzed using the semi-empirical equation of the
power law to describe drug release from polymeric nanoparticles. The fitting accuracy R2
and the n, k values are shown in Table 3.
Table 3. Power law parameters (n, K) and fitting accuracy R2 for DNA release from functionalized
and non-functionalized NCs.
R2 n K
Functionalized NCs 0.989 0.117 to 0.139 0.210 to 0.223
Non-functionalized NCs 0.818 0.052 to 0.133 0.298 to 0.369
Specifically, a high degree of correlation was obtained for both functionalized and
non-functionalized NCs, with a regression coefficient R2 = 0.989 for the functionalized NCs.
The R2 was lower for the non-functionalized NCs (R2 = 0.818), and this can be attributed to
the faster release of DNA in the very first hours. Moreover, the release order value n < 0.4
suggested a release mechanism governed by Fickian diffusion, which is typical of spherical
nanoparticles [54]. This suggests that there is no influence of macromolecular relaxation
phenomena as expected for cross-linked nanoparticles.
A wide selection of constructs which target FA receptors on cancer cells have been
developed. Although NP-based carriers allowed higher loading capacity, cytotoxicity is a
frequent side effect [70].
The cytotoxicity of NCs after functionalization was evaluated via MTT assay. The test
did not show any toxic effect on NIH3T3 cells, confirming that the presence of FA did not
affect the cytocompatibility of the NPs, thus supporting the potential use of the terpolymer-
based nanocarriers for drug delivery applications.
Finally, preliminary cell uptake tests carried out on cells over-expressing FA receptors
highlighted an increased ability of the functionalized NCs to actively target the cells than
the non-functionalized ones. HeLa cells are well known to have folic acid receptors on their
surface, making them suitable cells to test uptake of FA-functionalized nanoparticles [55].
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Our preliminary test on this cell line supports the idea that presence of targeting moieties
on the surface of the nanoparticles favors cell uptake due to a ligand-receptor-based
mechanism, thus opening up the possibility to more effective therapies. In addition
to this, direct molecular interaction of FA with cellular membranes of cancer cells has
been previously demonstrated not to be limited to this specific receptor-mediated contact,
highlighting the advantages of rational design of nanosystems as well as the possible
involvement of direct molecular interactions of FA with cellular membranes, not limited to
specific receptor recognition, in the mechanisms of their endocytosis [71].
Overall, these results are very promising and suggest that terpolymer-based NCs
could be a potential innovative system for the targeted delivery of nucleic acids to cancer
cells. Thanks to their cavity, NCs allows for a modulation of the release over time, and the
modification of their surface helps targeting the cells of interest. Future studies will be
focused on further investigation of the NC ability to target specific cancer cells (such as
ovarian cancer cells). Moreover, functionalized NCs will be tested in vivo on a murine
model of ovarian cancer, and their ability to accumulate in the diseased region upon
systemic injection will be investigated using imaging techniques.
5. Conclusions
In this study, terpolymer-based nanocapsules were developed via free radical poly-
merization of three distinct monomers around a preformed sacrificial core. The NCs were
loaded with DNA and functionalized with FA to obtain active targeting towards cancer
cells via a ligand-receptor-based mechanism. The NCs were able to encapsulate the DNA
and then release it over time in a controlled way, thanks to the hollow structure of the
particles that favored a modulation of the release. The modification of the NC surface led to
a carrier able to target HeLa cells overexpressing folate receptors, favoring cell uptake via a
ligand-receptor-based mechanism. Overall, these results are very promising and suggest
that terpolymer-based NCs could be a potential innovative system for the targeted delivery
of nucleic acids to cancer cells, opening up the possibility of more effective therapies.
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